Financial Performance - The group's revenue for the year ended December 31, 2025, was RMB 18,112.6 million, a decrease of 12.7% compared to the previous year[2]. - The group's gross profit for the same period was RMB 11,775.4 million, down 14.5% year-over-year[2]. - The net profit for the year was RMB 2,093.8 million, representing a significant decline of 42.7% from the previous year[2]. - Basic and diluted earnings per share were both RMB 0.21, compared to RMB 0.39 in 2024[2]. - The company reported a total comprehensive income of RMB 1,918.5 million for the year, down from RMB 3,570.1 million in 2024[5]. - The pre-tax profit for 2025 is RMB 6,337,185 thousand, down from RMB 6,983,747 thousand in 2024, indicating a decrease of about 9.3%[35]. - The company's net profit for the year dropped by 42.7% from RMB 3,654.1 million in 2024 to RMB 2,093.8 million in 2025[71]. - The pre-tax profit decreased by 39.6% from RMB 5,549.7 million in 2024 to RMB 3,352.2 million in 2025[69]. - The infant formula product revenue decreased by 16.8% from RMB 19,061.6 million in 2024 to RMB 15,868.3 million in 2025, representing 87.6% of total revenue[59]. Assets and Liabilities - Total assets as of December 31, 2025, were RMB 27,289.4 million, a decrease from RMB 29,134.7 million in 2024[6]. - Current assets decreased to RMB 20,257.2 million from RMB 22,248.6 million in the previous year[6]. - The total liabilities increased slightly to RMB 6,749.3 million from RMB 6,591.0 million in 2024[6]. - Non-current liabilities decreased from RMB 1,727,291 thousand in 2024 to RMB 1,167,941 thousand in 2025, a reduction of approximately 32.3%[7]. - Net asset value decreased from RMB 27,407,385 thousand in 2024 to RMB 26,121,488 thousand in 2025, a decline of about 4.7%[7]. - Total equity decreased from RMB 27,407,385 thousand in 2024 to RMB 26,121,488 thousand in 2025, representing a decrease of approximately 4.7%[7]. - The total liabilities for the year ending December 31, 2025, are RMB 7,917,258, a decrease from RMB 8,318,321 in 2024, representing a decline of approximately 4.8%[22][24]. Cash Flow and Capital Expenditure - The net cash flow from operating activities for the group in 2025 was RMB 2,213.8 million, compared to RMB 4,179.3 million in 2024[78]. - The net cash flow from investing activities in 2025 was RMB 9.6 million, a significant decrease from RMB 1,316.8 million in 2024[78]. - The group's total capital expenditure for the year ended December 31, 2025, was approximately RMB 1,519.8 million, mainly due to property, plant, and equipment investments[81]. Dividends - The board proposed a final dividend of HKD 0.1290 per share, down from HKD 0.1632 per share in 2024[2]. - The interim dividend declared per ordinary share is HKD 0.1209 for 2025, down from HKD 0.1632 in 2024, equivalent to about RMB 1.0 billion compared to RMB 1.35 billion in the previous year[38]. - The company proposed a final dividend of HKD 0.1290 per share for the year ending December 31, 2025, totaling approximately HKD 1,135,997,019 (equivalent to about RMB 1,000,000,000) pending shareholder approval[96]. - The dividend policy aims to distribute no less than 30% of the net profit for each fiscal year, subject to future investment plans[97]. Market and Industry Trends - China's birth rate has declined from 8.52‰ in 2020 to 5.63‰ in 2025, resulting in a decrease in newborns to approximately 7.9 million[45]. - The number of children aged 0-3 years is projected to decrease from approximately 41.9 million in 2020 to about 26.5 million in 2025, impacting the infant formula market[45]. - The average disposable income in China is expected to reach RMB 43,377 in 2025, with a compound annual growth rate of 6.1% from 2020 to 2025, enhancing demand for premium infant formula products[45]. - The Chinese government aims to maintain a 60% self-sufficiency level for domestically produced infant formula, encouraging the use of fresh milk in production[46]. - New national safety standards for infant formula were implemented in February 2023, setting stricter regulations on protein, carbohydrates, and micronutrients, benefiting leading companies in the industry[46]. - The government has introduced supportive measures for the three-child policy to counteract declining birth rates, including increased maternity benefits and healthcare insurance[46]. Company Operations and Strategy - The company was established in October 2012 and is engaged in the production and sale of dairy products and nutritional supplements[8]. - The company was listed on the Hong Kong Stock Exchange on November 13, 2019[9]. - The group has established 11 production facilities with a designed annual capacity of over 438,000 tons as of December 31, 2025[52]. - The group aims to optimize its production arrangements to enhance capacity and efficiency[52]. - The group offers a diversified product portfolio to meet a wide range of customer needs, including ultra-high-end and high-end categories[49]. - The group has implemented innovative online and offline marketing strategies to strengthen brand recognition in the Chinese infant formula market[53]. - The company has established an audit committee consisting of three members to oversee financial reporting and risk management[94]. - The audit committee reviewed the financial statements for the year ending December 31, 2025, ensuring compliance with accounting principles[94]. - The company maintains a commitment to corporate governance, adhering to the guidelines set forth by the Hong Kong Stock Exchange[89]. Share Buyback and Securities - The company repurchased a total of 259,587,000 shares during the reporting period, with a total cost of HKD 1,100,059,040[91]. - The highest price paid per share during the buyback was HKD 4.70, while the lowest was HKD 4.02[91]. - The board believes that the share buyback reflects confidence in the company's market position and long-term growth prospects[92]. - The company has not engaged in any other purchases or sales of its listed securities during the reporting period[91]. - The company will apply the remaining unutilized net proceeds from the global offering as outlined in the prospectus[93].
中国飞鹤(06186) - 2025 - 年度业绩